Overview

Actively managed equity portfolio investing worldwide in companies from the health transformation sector.

Efficient means of exploiting the potential of companies operating in the health Transformation area.

Specialised sector analysts seek out the attractive stocks in the Health Transformation area.

Investment decisions are based on a disciplined investment philosophy and fundamental research.

This fund promotes environmental, social and corporate governance characteristics. The research and portfolio construction processes incorporate ESG risk integration and screening and comply with UBS SA国际传谋 Sustainability exclusion policy. For more information on Sustainability at UBS, please refer to www.ubs.com/am-si-commitment.

The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

Benefits

The fund is pairing CIO identified investment themes with the stock selection and portfolio construction expertise of UBS SA国际传谋.

The fund taps into the knowledge of proven sector specialists.

UBS’s proprietary fundamental valuation approach allows consistent identification of the most attractive global health transformation companies.

Investors benefit from a global investment platform of UBS SA国际传谋.

Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. Sustainability risks are environmental, social or governance events or conditions that can have a material negative effect on the return, depending on the relevant sector, industry and company exposure. Sustainability risk: the risk arising from any environmental, social or governance events or conditions that, were they to occur, could cause a material negative impact on the value of the investment. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Features

Product category
UBS Equity Funds
UBS Sector Funds
Product domicile
Luxembourg
Portfolio management
UBS SA国际传谋 (Americas) LLC, New York
Fund management
UBS SA国际传谋 (Europe) S.A., Luxembourg
Custodian bank
UBS Europe SE, Luxembourg Branch
Representative for products established under foreign law
UBS AG, Stockholm
Day of inception
May 27, 1998
Currency of account
USD
Close of financial year
November 30
SFDR Classification
Art.8
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Ongoing costs p.a.
1.79% p.a.
Management fee
1.37% p.a.
Total expense ratio (TER)
1.78% p.a.
Swing pricing
yes
Minimum investment
n.a.
Reference Index / Benchmark
MSCI World Health Care (net div. reinv.)
ISIN
LU0085953304
Bloomberg Ticker
UBSEHLI LX
Telekurs Id
EQHC

Performance and Prices

Percentage growth

as of April 23, 2026
Cumulative
USD(%) EUR(%)
YTD
1M
3M
6M
1Y 19.98 16.29
2Y
3Y 26.52 18.55
5Y 29.30 33.03
ø p.a.5Y 5.27 5.87

Current data

Net asset value 23.04.2026 USD 501.81
High - last 12 months 27.02.2026 USD 530.52
Low - last 12 months 14.05.2025 USD 404.91
Assets of the unit class in mn 23.04.2026 USD 106.75
Total product assets in mn 23.04.2026 USD 266.73
Statistical data
Date
2 years
5 years
Total risk reference index / benchmark 31.03.2026 14.34% 14.13%
Sharpe Ratio 31.03.2026 0.09 0.13
Risk Free Rate 31.03.2026 4.55% 3.51%

Structures

By the 10 largest equity positions (in %, as of March 31, 2026)

 
 
Eli Lilly & Co 9.11
AstraZeneca PLC 8.83
UnitedHealth Group Inc 5.17
Sandoz Group AG 4.87
Novartis AG 4.84
Koninklijke Philips NV 4.81
Alcon AG 4.74
Bristol-Myers Squibb Co 4.18
Intuitive Surgical Inc 4.12
Chugai Pharmaceutical Co Ltd 4.03

Fees

Ongoing costs p.a.
1.79%
Flat fee
1.71%
Management fee p.a.
1.37%
Max. issuing commission
5.00%
Max. redemption commission
0.00%
Distribution fee
(see info)

Distributions

No distributions. Continuous reinvestment of income.

Sales Authorisations

Market
Sales authorisations status
Austria
Registered
Chile
Institutional Only*
Cyprus
Registered
Denmark
Registered
Finland
Registered
Germany
Registered
Greece
Registered
Iceland
Registered
Italy
Registered
Liechtenstein
Registered
Luxembourg
Registered
Malta
Registered
Netherlands
Registered
Norway
Registered
Portugal
Registered
Singapore
Institutional Only*
Spain
Registered
Sweden
Registered
Switzerland
Registered
Taiwan
Registered
United Kingdom
Registered

Literature

Brochures
Document type
Document Language
Fact Sheet
Manager Commentary
Fact Sheet - UBS Equity Funds
Fact Sheet - UBS Sector Funds
Agreement / Prospectus
Document type
Document Language
Prospectus
Key Information Document
Past performance
Previous performance scenario
Statutes / Management regulations
ESG Disclosure
SFDR Pre-Contractual Annex
Annual and semi-annual report (accounting on November 30)
Document type
Document Language
Annual report
SFDR Periodic Report Annex
Semi-annual report
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.